Interleukin-10 in cancer immunotherapy: from bench to bedside

Mohamad Adham Salkeni; Aung Naing

doi:10.1016/j.trecan.2023.05.003

Interleukin-10 in cancer immunotherapy: from bench to bedside

Trends Cancer. 2023 Sep;9(9):716-725. doi: 10.1016/j.trecan.2023.05.003. Epub 2023 Jun 14.

Authors

Mohamad Adham Salkeni¹, Aung Naing²

Affiliations

¹ Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
² Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: anaing@mdanderson.org.

PMID: 37321942
PMCID: PMC10524969 (available on 2024-09-01)
DOI: 10.1016/j.trecan.2023.05.003

Abstract

Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.

Keywords: T cell; cancer; inflammation; interleukin 10; pegilodecakin; pegylated IL-10.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Cytokines
Humans
Immunotherapy / methods
Interleukin-10* / pharmacology
Neoplasms* / therapy
Tumor Microenvironment

Substances

Interleukin-10
Cytokines

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States